Galectin Therapeutics (GALT) Non-Current Assets (2010 - 2026)
Galectin Therapeutics' quarterly Non-Current Assets came in at $68000.0 in Q1 2026, down 72.02% year-on-year from $243000.0 in Q1 2025, and down 29.17% quarter-over-quarter from $96000.0 in Q4 2025.
Galectin Therapeutics has reported Non-Current Assets for 17 years, with the latest figure at $68000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 72.02% year-over-year to $68000.0; the trailing twelve-month figure through Mar 2026 stood at $475000.0 (down 59.05% YoY), and the FY2025 full-year result was $96000.0, down 60.49% from the prior year.
- Non-Current Assets for Q1 2026 stood at $68000.0, down from $96000.0 in the prior quarter.
- The five-year high for Non-Current Assets was $793000.0 in Q3 2022, with the low at $68000.0 in Q1 2026.
- Average Non-Current Assets over 5 years is $360470.6, with a median of $306000.0 recorded in 2024.
- Year-over-year, Non-Current Assets soared 10371.43% in 2022 and sank 72.02% in 2026.
- Tracing GALT's Non-Current Assets over 5 years: stood at $733000.0 in 2022, then plunged by 33.15% to $490000.0 in 2023, then plunged by 50.41% to $243000.0 in 2024, then plunged by 60.49% to $96000.0 in 2025, then retreated by 29.17% to $68000.0 in 2026.
- The last three Non-Current Assets figures came in at $68000.0 (Q1 2026), $96000.0 (Q4 2025), and $136000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | 68,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68,000.00 |
| Dec 31, 2025 | 96,000.00 |
| Sep 30, 2025 | 136,000.00 |
| Jun 30, 2025 | 175,000.00 |
| Mar 31, 2025 | 243,000.00 |
| Dec 31, 2024 | 243,000.00 |
| Sep 30, 2024 | 306,000.00 |
| Jun 30, 2024 | 368,000.00 |
| Mar 31, 2024 | 430,000.00 |
| Dec 31, 2023 | 490,000.00 |
| Sep 30, 2023 | 552,000.00 |
| Jun 30, 2023 | 613,000.00 |
| Mar 31, 2023 | 673,000.00 |
| Dec 31, 2022 | 733,000.00 |
| Sep 30, 2022 | 793,000.00 |
| Jun 30, 2022 | 101,000.00 |
| Mar 31, 2022 | 108,000.00 |
| Dec 31, 2021 | 7,000.00 |
| Sep 30, 2021 | 40,000.00 |
| Jun 30, 2021 | 71,000.00 |
| Mar 31, 2021 | 103,000.00 |
| Dec 31, 2020 | 135,000.00 |
| Sep 30, 2020 | 166,000.00 |
| Jun 30, 2020 | 197,000.00 |
| Mar 31, 2020 | 227,000.00 |
| Dec 31, 2019 | 258,000.00 |
| Sep 30, 2019 | 287,000.00 |
| Jun 30, 2019 | 317,000.00 |
| Mar 31, 2019 | 347,000.00 |
| Dec 31, 2018 | 174,000.00 |
| Sep 30, 2018 | 86,000.00 |
| Jun 30, 2018 | 172,000.00 |
| Mar 31, 2018 | 258,000.00 |
| Dec 31, 2017 | 342,000.00 |
| Dec 31, 2016 | 1,000.00 |
| Sep 30, 2016 | 3,000.00 |
| Jun 30, 2016 | 5,000.00 |
| Mar 31, 2016 | 7,000.00 |
| Dec 31, 2015 | 8,000.00 |
| Sep 30, 2015 | 10,000.00 |
| Jun 30, 2015 | 12,000.00 |
| Mar 31, 2015 | 14,000.00 |
| Dec 31, 2014 | 16,000.00 |
| Sep 30, 2014 | 28,000.00 |
| Jun 30, 2014 | 84,000.00 |
| Mar 31, 2014 | 154,000.00 |
| Dec 31, 2013 | 26,000.00 |
| Sep 30, 2013 | 35,000.00 |
| Jun 30, 2013 | 38,000.00 |
| Mar 31, 2013 | 41,000.00 |
| Dec 31, 2012 | 44,000.00 |
| Sep 30, 2012 | 45,000.00 |
| Jun 30, 2012 | 107,000.00 |
| Mar 31, 2012 | 109,000.00 |
| Dec 31, 2011 | 111,000.00 |
| Sep 30, 2011 | 108,000.00 |
| Jun 30, 2011 | 105,000.00 |
| Dec 31, 2010 | 105,000.00 |